Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air, Inc. filed Amendment No. 1 to its shelf registration statement on Form S-3 primarily as a technical update. The amendment is described as being filed solely to revise Item 16 of Part II in order to add the legal opinion of Sichenzia Ross Ference Carmel LLP as Exhibit 5.1 and the related consent as Exhibit 23.3, while leaving all other parts of the registration statement unchanged.
The filing also restates the full exhibit list, which includes prior merger agreements, certificates of incorporation and amendments, multiple warrant and securities purchase agreements, loan and security agreements, equity incentive and compensation plans, and an at-the-market equity offering sales agreement. It concludes with signatures from the chief executive officer, chief financial officer, and directors, along with a power of attorney authorizing designated officers to sign future amendments related to this registration.
Beyond Air, Inc. (XAIR) filed an S-3 shelf registration that includes an At-The-Market (ATM) equity program with BTIG allowing up to $35,000,000 of Common Stock sales. The company agreed to pay the agent a 3.0% cash commission and reimburse certain expenses. Reported issuances under the ATM were 564,699 shares for $2.5 million during the quarter ended June 30, 2025, and 1,877,076 shares for $5.8 million from July 1, 2025 through September 24, 2025. The prospectus includes standard risk-factor language noting the company expects to incur losses for the next few years and lists typical commercialization, regulatory, intellectual property, personnel, and growth-management risks.
Beyond Air, Inc. filed an 8-K describing terms that limit the number of common shares issuable on exercise of certain warrants to prevent a holder from exceeding a stated "Beneficial Ownership Limitation." If an exercise would push the holder past that limit, the company will only issue the number of shares that keep the holder below the limit and will hold the remaining shares in abeyance until the holder notifies the company that issuance would comply with the limitation.
The filing lists exhibits including a Form of New Warrant, a Form of Inducement Letter, and a Press Release dated September 8, 2025. The filing also identifies Steven A. Lisi by name.
Beyond Air, Inc. filed a report describing that its subsidiary NeuroNOS Limited has been granted U.S. Food and Drug Administration Orphan Drug Designation for BA-101, its lead investigational therapy for treating glioblastoma. This status applies to serious rare diseases and can provide development incentives. The company released a press release with more details, furnished as an exhibit, and notes that this information is provided under Regulation FD and is not deemed filed for liability purposes or automatically incorporated into other securities law filings.
Robert Scott Goodman, a director of Beyond Air, Inc. (XAIR), received a grant of stock options on 08/14/2025. The option grant is for 3,750 stock options with an exercise price of $2.45 per share and an expiration date of 08/14/2035. The option vests 25% on December 31, 2025, with the remainder vesting in equal annual installments on each December 31 for the next three years. After the grant, the reporting person beneficially owns 5,750 shares of common stock, which includes an additional 2,000 stock split-adjusted shares noted in the filing.
Beyond Air, Inc. filed a current report to note that it has issued a press release announcing its financial results for the first quarter ended June 30, 2025. The company stated that the press release, dated August 12, 2025, is attached as Exhibit 99.1 and is incorporated by reference into this report. The information in this report and the attached press release is being furnished rather than filed under securities laws, which affects how it is treated for certain liability and incorporation purposes.
Balyasny Asset Management and affiliated entities disclose beneficial ownership of 12,290,913 shares of Beyond Air common stock, representing approximately 9.99% of the outstanding class based on the issuer's reported share count. The reported position includes 8,956,504 shares issuable upon exercise of warrants, but a contractual 9.99% blocker prevents the Reporting Persons from exercising any warrants that would result in ownership above 9.99%.
The filing states each Reporting Person has sole voting and dispositive power over the 12,290,913 shares and identifies ADMF as the direct holder and an investment management client of BAM with rights to dividends and sale proceeds. Filers certify the securities were acquired in the ordinary course of business and not to influence control.
Beyond Air reported operational progress but faces a near-term funding gap. Revenue for the three months ended June 30, 2025 rose to $1.76 million from $0.68 million a year earlier, producing a $156,000 gross profit versus a prior gross loss. Operating losses narrowed to $7.62 million and net loss improved to $8.08 million from $13.06 million, reflecting lower R&D and SG&A spend. The company held $6.63 million of cash, marketable securities and restricted cash at period end but used $4.53 million in operating cash flow during the quarter. Management disclosed substantial doubt about meeting obligations with current resources and stated additional funding will be required within one year. Financing actions during the quarter included $2.4 million net ATM proceeds and a $2.0 million related-party advance; long-term debt outstanding under the Loan Agreement remains $11.5 million (facility terms include a 15% annual interest structure). The company has FDA PMA for LungFit PH and CE mark approval for additional indications, and effected a one-for-twenty reverse stock split with retroactive presentation of prior-period per-share amounts.